Skip to content

THE EFFECTS OF THAI HERBAL WATTANA FORMULA ON PLATELET AGGREGATION AND METABOLIC PROFILE OF HEALTHY VOLUNTEERS AND THE RELATIONSHIP WITH INNATE DHATU CHAO RUEAN

THE EFFECTS OF THAI HERBAL WATTANA FORMULA ON PLATELET AGGREGATION AND METABOLIC PROFILE OF HEALTHY VOLUNTEERS AND THE RELATIONSHIP WITH INNATE DHATU CHAO RUEAN

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20221213002
Enrollment
40
Registered
2022-12-13
Start date
2020-03-06
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PLATELET AGGREGATION THAI HERBAL WATTANA FORMULA HERBAL MEDICINE PLATELET AGGREGATION INNATE DHATU RUEAN METABOLOMICS

Interventions

Received a single dose of WNF 1,000 mg
Experimental Drug
THAI HERBAL WATTANA FORMULA

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
32 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male or female Thai nationality greater than or equal to 32 years at enrollment 2. Body mass index (BMI) between 18-24 kg/m2 3. Healthy as confirmed by blood chemistry especially AST less than or equal to 40 U/L (in male), less than or equal to 32 U/L (in female); ALT less than or equal to 41 U/L (in male), less than or equal to 33 U/L (in female); ALP less than or equal to 141 U/L (in male), less than or equal to 105 U/L (in female) and GFR greater than or equal to 60 ml/min/1.73m2 4. Willingness to participate in the study and sign the informed consent

Exclusion criteria

Exclusion criteria: 1. Evidence of allergic reactions from herbal medicine 2. History of taking coffee, tea or caffeinated beverages consumption within 14 days before the study 3. History of taking dietary supplements and vitamins within 14 days before the study 4. Habitual smoking and cannot instruct to abstain from cigarettes during the study 5. History of excess alcohol ingestion and cannot instruct to abstain from alcohol during the study or drug abuse 6. Pregnant or breastfeeding 7. History of blood donated or received within 3 months before the study 8. History of participated in the research study within 30 days

Design outcomes

Primary

MeasureTime frame
PLATELET AGGREGATION at 3, 6, and 24 hours after dosing Aggregation platelet status/ Percent platelet aggregation

Secondary

MeasureTime frame
plasma metabolomics at 3, 6, and 24 hours after dosing plasma metabolic profiles perform by PCA, OPLS-DA,S-Plot

Countries

Thailand

Contacts

Public ContactSuveerawan Limsuvan

Faculty of Medicine Siriraj Hospital, Mahidol University

suveerawan.lim@mahidol.edu0830918591

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026